Alto neuroscience identifies biomarker and reports positive pharmacodynamic results from exploratory phase 2 proof-of-concept trial of alto-203

Mountain view, calif.--(business wire)---- $anro #precisionpsychiatry--alto neuroscience, inc. (“alto”) (nyse: anro) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory phase 2 proof-of-concept (poc) trial of alto-203 in major depressive disorder (mdd) patients with elevated levels of anhedonia. alto-203 is a novel, oral, h.
ALTO Ratings Summary
ALTO Quant Ranking